Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?-Reference-Cited by-同舟云学术

Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?

Published:2024-06-26 Issue:13 Volume:16 Page:2331
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Gómez-Aparicio María¹,López-Campos Fernando²³^ORCID,Buchser David⁴,Lazo Antonio⁵,Willisch Patricia⁶^ORCID,Ocanto Abrahams³^ORCID,Sargos Paul⁷,Shelan Mohamed⁸^ORCID,Couñago Felipe³^ORCID

Affiliation:

1. Department of Radiation Oncology, Hospital Universitario de Toledo, 45007 Toledo, Spain

2. Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain

3. Department of Radiation Oncology, Hospital Universitario San Francisco de Asis and Hospital Vithas La Milagrosa, GenesisCare, 28002 Madrid, Spain

4. Department of Radiation Oncology, Hospital Universitario Cruces, 48903 Barakaldo, Spain

5. Department of Radiation Oncology, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain

6. Department of Radiation Oncology, Hospital Meixoeiro, 36214 Vigo, Spain

7. Department of Radiation Oncology, Institut Bergonié, 33000 Bordeaux, France

8. Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Switzerland

Abstract

The treatment landscape for metastatic hormone-sensitive prostate cancer continues to evolve, with systemic treatment being the mainstay of current treatment. Prognostic and predictive factors such as tumour volume and disease presentation have been studied to assess responses to different treatments. Intensification and de-escalation strategies arouse great interest, so several trials are being developed to further personalize the therapy in these populations. Is there an optimal sequence and a possible option to de-intensify treatment in selected patients with a favourable profile? This and other goals will be the subject of this review.

Publisher

MDPI AG

Link

https://www.mdpi.com/2072-6694/16/13/2331/pdf

Reference73 articles.

1. Hormone sensitive protocol for metastatic prostate cancer, an update;Calleja;Actas Urológicas Españolas,2023

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clin.,2021

3. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study;Chi;J. Clin. Oncol.,2021

4. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer;Armstrong;J. Clin. Oncol.,2019

5. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial;Fizazi;Lancet Oncol.,2019